blonanserin has been researched along with perospirone in 2 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (perospirone) | Trials (perospirone) | Recent Studies (post-2010) (perospirone) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 111 | 24 | 26 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Naito, AT; Sugiyama, A | 1 |
1 review(s) available for blonanserin and perospirone
| Article | Year |
|---|---|
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Glycated Hemoglobin; Heart; Humans; Isoindoles; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Risk; Schizophrenia; Thiazoles; Weight Gain | 2014 |
1 other study(ies) available for blonanserin and perospirone
| Article | Year |
|---|---|
Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Calcium Channel Agonists; Cardiac Conduction System Disease; Delirium; Dogs; Dopamine Antagonists; Dose-Response Relationship, Drug; Electrocardiography; Female; Halothane; Heart Conduction System; Humans; Isoindoles; Long QT Syndrome; Middle Aged; Models, Animal; Piperazines; Piperidines; Potassium Channel Blockers; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Thiazoles; Torsades de Pointes | 2020 |